Valérie Jullian Selected Research

Hairy Cell Leukemia

12/2012

Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Valérie Jullian Research Topics

Disease

3	Neoplasms (Cancer) 07/2017 - 12/2012
3	Malaria 07/2017 - 10/2009
1	Body Weight (Weight, Body) 07/2021
1	Edema (Dropsy) 07/2021
1	Inflammation (Inflammations) 07/2021
1	Necrosis 07/2021
1	Cutaneous Leishmaniasis 07/2014
1	Melanoma (Melanoma, Malignant) 12/2012
1	Hairy Cell Leukemia 12/2012
1	Neuroblastoma 08/2012
1	Adenocarcinoma 04/2011

Drug/Important Bio-Agent (IBA)

3	simalikalactone EIBA 07/2017 - 12/2012
1	ChalconesIBA 07/2021
1	Chalcone (Benzalacetophenone)IBA 07/2021
1	Antimalarials (Antimalarial Agents)IBA 03/2015
1	fagaridineIBA 07/2014
1	chelerythrineIBA 07/2014
1	Imatinib Mesylate (Gleevec)FDA Link 12/2012
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2012
1	U 0126 (UO 126)IBA 12/2012
1	CiguatoxinsIBA 08/2012
1	Protein Kinases (Protein Kinase)IBA 04/2011
1	Herbal TeasIBA 10/2009
1	TeaIBA 10/2009

Therapy/Procedure

1	Therapeutics 03/2012